Close
  • Home

Archive - August 2020

ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
DualityBio’s DB-1317 granted FDA Fast Track Designation for advanced PDAC
28 August 2026
Regulatory
SOTIO’s SOT106 granted FDA Fast Track Designation for Soft Tissue Sarcoma
28 August 2026
Regulatory
Akeso’s AK157D1 cleared for phase 1 trial in Solid tumors
21 August 2026
Regulatory
CStone Pharmaceuticals receives NMPA IND approval for CS5007
21 August 2026
Regulatory
Celltrion’s CT-P73 receives US FDA FTD for recurrent/metastatic Cervical cancer
14 August 2026
Regulatory
ITM receives Complete Response Letter for ITM-11
14 August 2026

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id